Schistosomiasis: Drugs used and treatment strategies

• Published in: Acta tropica Vol. 176; pp. 179 - 187
• Main Authors: Siqueira, Lidiany da Paixão, Fontes, Danilo Augusto Ferreira, Aguilera, Cindy Siqueira Britto, Timóteo, Taysa Renata Ribeiro, Ângelos, Matheus Alves, Silva, Laysa Creusa Paes Barreto Barros, de Melo, Camila Gomes, Rolim, Larissa Araújo, da Silva, Rosali Maria Ferreira, Neto, Pedro José Rolim
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.12.2017
• Subjects: Animals; Anthelmintics - therapeutic use; Biomedical Research; Brazil; Child; Female; Humans; Neglected Diseases - drug therapy; Neglected tropical diseases; Oxamniquine - therapeutic use; Praziquantel - therapeutic use; Schistosoma haematobium; Schistosoma japonicum; Schistosoma mansoni; Schistosomiasis - drug therapy; Schistosomiasis - epidemiology; Schistosomicides; Treatment; Water Microbiology; Neglected tropical diseases; Schistosomicides; Treatment
• ISSN: 0001-706X; 1873-6254
• DOI: 10.1016/j.actatropica.2017.08.002

•Public politics must be more effective for the endemic control of schistosomiasis.•The number of drugs used to treat NTDs is very small, because that the investment in R&D for such diseases is inadequate.•Currently, some pharmaceutical companies have R&D units with major university centers focusing on the neglected diseases. Neglected tropical diseases (NTDs) affect millions of people in different geographic regions, especially the poorest and most vulnerable. Currently NTDs are prevalent in 149 countries, seventeen of these neglected tropical parasitic diseases are classified as endemic. One of the most important of these diseases is schistosomiasis, also known as bilharzia, a disease caused by the genus Schistosoma. It presents several species, such as Schistosoma haematobium, Schistosoma japonicum and Schistosoma mansoni, the latter being responsible for parasitosis in Brazil. Contamination occurs through exposure to contaminated water in the endemic region. This parasitosis is characterized by being initially asymptomatic, but it is able to evolve into more severe clinical forms, potentially causing death. Globally, more than 200 million people are infected with one of three Schistosome species, including an estimated 40 million women of reproductive age. In Brazil, about 12 million children require preventive chemotherapy with anthelmintic. However, according to the World Health Organization (WHO), only about 15% of the at-risk children receive regular treatment. The lack of investment by the pharmaceutical industry for the development and/or improvement of new pharmaceutical forms, mainly aimed at the pediatric public, is a great challenge. Currently, the main forms of treatment used for schistosomiasis are praziquantel (PZQ) and oxaminiquine (OXA). PZQ is the drug of choice because it presents as a high-spectrum anthelmintic, used in the treatment of all known species of schistosomiasis and some species of cestodes and trematodes. OXA, however, is not active against the three Schistosome species. This work presents a literature review regarding schistosomiasis. It addresses points such as available treatments, the role of the pharmaceutical industry against neglected diseases, and perspectives for treatment.